Burzynski Research Institute Inc (BZYR) Financial Statements (2024 and earlier)
Company Profile
| Business Address |
12000 RICHMOND AVE HOUSTON, TX 77082 |
| State of Incorp. | DE |
| Fiscal Year End | February 28 |
| Industry (SIC) | 2835 - In Vitro and In Vivo Diagnostic Substances (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) (USD)Annual | Quarterly
| 11/30/2023 Q3 | 8/31/2023 Q2 | 5/31/2023 Q1 | 2/28/2023 Q4 | 11/30/2022 Q3 | 8/31/2022 Q2 | 5/31/2022 Q1 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 1,397 | 148 | 934 | 1,692 | 1,266 | 4,766 | |||
| Cash and cash equivalents | 1,397 | 148 | 934 | 1,692 | 1,266 | 4,766 | |||
| Prepaid expense | 400 | 700 | 1,000 | 100 | 400 | 700 | |||
| Total current assets: | 1,797 | 848 | 1,934 | 1,792 | 1,666 | 5,466 | |||
| Noncurrent Assets | |||||||||
| TOTAL ASSETS: | 1,797 | 848 | 1,934 | 1,792 | 1,666 | 5,466 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 6,273 | 71,366 | 15,661 | 28,420 | 15,304 | 44,146 | |||
| Accounts payable | 22,757 | 12,570 | 16,650 | 1,935 | 13,925 | ||||
| Accrued liabilities | 6,273 | 48,609 | 3,091 | 11,770 | 13,369 | 30,221 | |||
| Total current liabilities: | 6,273 | 71,366 | 15,661 | 28,420 | 15,304 | 44,146 | |||
| Noncurrent Liabilities | |||||||||
| Total liabilities: | 6,273 | 71,366 | 15,661 | 28,420 | 15,304 | 44,146 | |||
| Equity | |||||||||
| Equity, attributable to parent | (4,476) | (70,518) | (13,727) | (26,628) | (13,638) | (38,680) | |||
| Common stock | 131,449 | 131,449 | 131,449 | 131,449 | 131,449 | 131,449 | |||
| Additional paid in capital | 127,158,359 | 126,840,213 | 126,609,599 | 126,380,700 | 126,141,051 | 125,900,091 | |||
| Accumulated deficit | (127,294,284) | (127,042,180) | (126,754,775) | (126,538,777) | (126,286,138) | (126,070,220) | |||
| Total equity: | (4,476) | (70,518) | (13,727) | (26,628) | (13,638) | (38,680) | |||
| TOTAL LIABILITIES AND EQUITY: | 1,797 | 848 | 1,934 | 1,792 | 1,666 | 5,466 | |||
Income Statement (P&L) (USD)Annual | Quarterly
| 11/30/2023 Q3 | 8/31/2023 Q2 | 5/31/2023 Q1 | 2/28/2023 Q4 | 11/30/2022 Q3 | 8/31/2022 Q2 | 5/31/2022 Q1 | ||
|---|---|---|---|---|---|---|---|---|
| Operating expenses | (252,104) | (287,405) | (110,515) | (252,639) | (215,918) | (231,737) | ||
| Operating loss: | (252,104) | (287,405) | (110,515) | (252,639) | (215,918) | (231,737) | ||
| Loss from continuing operations: | (252,104) | (287,405) | (110,515) | (252,639) | (215,918) | (231,737) | ||
| Loss before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | ✕ | ✕ | (215,918) | (231,737) | |
| Net loss available to common stockholders, diluted: | (252,104) | (287,405) | (110,515) | (252,639) | (215,918) | (231,737) | ||
Comprehensive Income (USD)Annual | Quarterly
| 11/30/2023 Q3 | 8/31/2023 Q2 | 5/31/2023 Q1 | 2/28/2023 Q4 | 11/30/2022 Q3 | 8/31/2022 Q2 | 5/31/2022 Q1 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (252,104) | (287,405) | (110,515) | (252,639) | (215,918) | (231,737) | ||
| Comprehensive loss, net of tax, attributable to parent: | (252,104) | (287,405) | (110,515) | (252,639) | (215,918) | (231,737) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.